Low‐dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long‐term outcome from a single center experience

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|90|11|970-974

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.11, 2015-11, pp. : 970-974

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high‐risk relapsed/refractory chronic lymphocytic leukemia patients

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 1, 2015-01 ,pp. : 37-42

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long-Term Administration of Oral Low-Dose Topoisomerase II Inhibitors, MST-16 and VP-16, for Refractory or Relapsed Non-Hodgkin’s Lymphoma

By  

Acta Haematologica, Vol. 104, Iss. 2-3, 2001-01 ,pp. : 128-130

Karger

Access to resources Recommend Favorite

Long‐term outcomes for patients with acute myeloid leukemia: A single‐center experience from AIIMS, India

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 3, 2015-09 ,pp. : 242-252

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 5, 2015-05 ,pp. : 417-421

John Wiley & Sons Inc

Access to resources Recommend Favorite

Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based regimens

By  

CANCER, Vol. 121, Iss. 20, 2015-10 ,pp. : 3612-3621

John Wiley & Sons Inc

Access to resources Recommend Favorite